Nyrada Inc. announced the appointment of Dr. Gisela Mautner as a Non-Executive Director to its Board. The Company also announced the retirement of Non-Executive Director, Peter Marks. Mr. Marks has been a member of the Board since before the Company listed in January 2020 and retires from the Nyrada Board to pursue a range of other interests.

Both Board changes are effective from 1 August 2022. Dr. Mautner is a medical doctor with extensive pharmaceutical industry experience encompassing all aspects of drug development, from clinical research through to product commercialisation. She is a seasoned senior leader, having held positions at MSD (Merck), Bayer and Amgen, where she successfully launched several new drugs in different therapeutic areas, including in cardiovascular diseases.

Dr. Mautner is the Chief Executive Officer and Managing Director of Noxopharm, previously serving as its Chief Medical Officer since 2019 (Noxopharm has a significant holding in Nyrada). She holds a Doctor of Medicine and PhD from Germany, a Master of Public Health from Harvard University, and a Master of Business Administration from Northwestern University of Chicago. Dr. Mautner will stand for election at Nyrada's AGM in November 2022.